Education
About Us
Working with TipRanks
Follow Us
Piramal Pharma Limited (IN:PPLPHARMA)
:PPLPHARMA
Total Valuation
Piramal Pharma Limited has a market cap or net worth of ₹259.80B. The enterprise value is ₹340.30B.
Market Cap₹259.80B
Enterprise Value₹340.30B
Share Statistics
Piramal Pharma Limited has 1,329,248,200 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,329,248,200
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Piramal Pharma Limited’s return on equity (ROE) is 0.01 and return on invested capital (ROIC) is 5.90%.
Return on Equity (ROE)0.01
Return on Assets (ROA)<0.01
Return on Invested Capital (ROIC)5.90%
Return on Capital Employed (ROCE)0.30
Revenue Per Employee13.62M
Profits Per Employee135.63K
Employee Count6,719
Asset Turnover0.58
Inventory Turnover1.40
Valuation Ratios
The current PE Ratio of Piramal Pharma Limited is 268.4. Piramal Pharma Limited’s PEG ratio is 0.84.
PE Ratio268.4
PS Ratio3.30
PB Ratio3.72
Price to Fair Value3.72
Price to FCF132.61
Price to Operating Cash Flow0.00
PEG Ratio0.84
Income Statement
In the last 12 months, Piramal Pharma Limited had revenue of 91.51B and earned 911.30M in profits. Earnings per share was 0.69.
Revenue91.51B
Gross Profit59.20B
Operating Income36.12B
Pretax Income4.15B
Net Income911.30M
EBITDA14.04B
Earnings Per Share (EPS)0.69
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Piramal Pharma Limited pays an annual dividend of ₹0.14, resulting in a dividend yield of 0.07%
Dividend Per Share₹0.14
Dividend Yield0.07%
Payout Ratio23.93%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.69
52-Week Price Change-12.74%
50-Day Moving Average195.71
200-Day Moving Average211.55
Relative Strength Index (RSI)48.09
Average Volume (3m)207.00K
Important Dates
Piramal Pharma Limited upcoming earnings date is Oct 23, 2025, During Market Hours (Confirmed).
Last Earnings DateJul 28, 2025
Next Earnings DateOct 23, 2025
Ex-Dividend DateJul 16, 2025
Financial Position
Piramal Pharma Limited as a current ratio of 1.54, with Debt / Equity ratio of 59.77%
Current Ratio1.54
Quick Ratio0.93
Debt to Market Cap0.16
Net Debt to EBITDA3.10
Interest Coverage Ratio8.57
Taxes
In the past 12 months, Piramal Pharma Limited has paid 3.24B in taxes.
Income Tax3.24B
Effective Tax Rate0.78
Enterprise Valuation
Piramal Pharma Limited EV to EBITDA ratio is 24.63, with an EV/FCF ratio of 151.72.
EV to Sales3.78
EV to EBITDA24.63
EV to Free Cash Flow151.72
EV to Operating Cash Flow38.75
Balance Sheet
Piramal Pharma Limited has ₹4.08B in cash and marketable securities with ₹0.00 in debt, giving a net cash position of ₹4.08B billion.
Cash & Marketable Securities₹4.08B
Total Debt₹0.00
Net Cash₹4.08B
Net Cash Per Share₹3.07
Tangible Book Value Per Share₹30.14
Margins
Gross margin is 56.17%, with operating margin of 39.47%, and net profit margin of 1.00%.
Gross Margin56.17%
Operating Margin39.47%
Pretax Margin4.53%
Net Profit Margin1.00%
EBITDA Margin15.34%
EBIT Margin6.87%
Analyst Forecast
The average price target for Piramal Pharma Limited is ₹271.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target₹271.67
Price Target Upside39.00% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast9.08%
EPS Growth Forecast249.08%